Cancer Pain – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cancer Pain – Pipeline Review, H2 2016’, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cancer Pain

The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects

The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cancer Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cancer Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexza Pharmaceuticals Inc

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

AstraZeneca Plc

Benitec Biopharma Ltd

BioDelivery Sciences International Inc

ChironWells GmbH

Colby Pharmaceutical Company

Daiichi Sankyo Company Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Grunenthal GmbH

GW Pharmaceuticals Plc

Hisamitsu Pharmaceutical Co Inc

Immupharma Plc

IntelGenx Corp

iX Biopharma Ltd

Kancera AB

Klaria Pharma Holding AB

Komipharm International Co Ltd

KPI Therapeutics Inc

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Orion Oyj

Pain Therapeutics Inc

Pfizer Inc

Pharmaleads SA

Recordati SpA

Ribomic Inc.

Trillium Therapeutics Inc

Virobay Inc

WEX Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cancer Pain Overview 8

Therapeutics Development 9

Pipeline Products for Cancer Pain - Overview 9

Pipeline Products for Cancer Pain - Comparative Analysis 10

Cancer Pain - Therapeutics under Development by Companies 11

Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13

Cancer Pain - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Cancer Pain - Products under Development by Companies 18

Cancer Pain - Products under Investigation by Universities/Institutes 21

Cancer Pain - Companies Involved in Therapeutics Development 22

Alexza Pharmaceuticals Inc 22

AngioChem Inc 23

Aoxing Pharmaceutical Company Inc 24

Aphios Corp 25

AstraZeneca Plc 26

Benitec Biopharma Ltd 27

BioDelivery Sciences International Inc 28

ChironWells GmbH 29

Colby Pharmaceutical Company 30

Daiichi Sankyo Company Ltd 31

Dompe Farmaceutici SpA 32

Fujimoto Pharmaceutical Corp 33

Grunenthal GmbH 34

GW Pharmaceuticals Plc 35

Hisamitsu Pharmaceutical Co Inc 36

Immupharma Plc 37

IntelGenx Corp 38

iX Biopharma Ltd 39

Kancera AB 40

Klaria Pharma Holding AB 41

Komipharm International Co Ltd 42

KPI Therapeutics Inc 43

Neurocentrx Pharma Ltd 44

Nippon Kayaku Co Ltd 45

Orion Oyj 46

Pain Therapeutics Inc 47

Pfizer Inc 48

Pharmaleads SA 49

Recordati SpA 50

Ribomic Inc. 51

Trillium Therapeutics Inc 52

Virobay Inc 53

WEX Pharmaceuticals Inc 54

Zynerba Pharmaceuticals Inc 55

Cancer Pain - Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 60

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

ANG-2002 - Drug Profile 67

AQU-118 - Drug Profile 68

AZD-8797 - Drug Profile 69

BBI-11008 - Drug Profile 71

buprenorphine hydrochloride - Drug Profile 72

cebranopadol - Drug Profile 73

CPC-111 - Drug Profile 76

crotalphine - Drug Profile 77

CSTI-200 - Drug Profile 78

dexmedetomidine hydrochloride - Drug Profile 79

dronabinol - Drug Profile 81

Drug 1 for Migraine and Cancer Pain - Drug Profile 82

Drug 2 for Migraine and Cancer Pain - Drug Profile 83

Drug 3 for Migraine and Cancer Pain - Drug Profile 84

Drug for Cancer Neuropathic Pain - Drug Profile 85

Drug for Migraine and Cancer Pain - Drug Profile 86

fentanyl - Drug Profile 87

fentanyl citrate - Drug Profile 88

fentanyl citrate - Drug Profile 90

fentanyl citrate - Drug Profile 91

fentanyl citrate ER - Drug Profile 92

gabapentin - Drug Profile 93

HP-3150 - Drug Profile 94

HS-198 - Drug Profile 95

hydromorphone hydrochloride - Drug Profile 96

HYLP-002 - Drug Profile 97

INT-0010 - Drug Profile 98

IPP-102199 - Drug Profile 99

methadone hydrochloride - Drug Profile 100

nabiximols - Drug Profile 101

Nervarna - Drug Profile 108

PAX-1 - Drug Profile 109

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile 110

Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 111

PL-265 - Drug Profile 112

QX-314 - Drug Profile 113

RBM-004 - Drug Profile 114

RBM-007 - Drug Profile 115

resiniferatoxin - Drug Profile 116

saracatinib difumarate - Drug Profile 118

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 122

Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 123

tanezumab - Drug Profile 124

Tetrodotoxin - Drug Profile 127

tilidine hydrochloride - Drug Profile 129

U-2902 - Drug Profile 130

VBY-825 - Drug Profile 132

zucapsaicin - Drug Profile 133

ZYN-001 - Drug Profile 135

Cancer Pain - Dormant Projects 137

Cancer Pain - Discontinued Products 141

Cancer Pain - Product Development Milestones 142

Featured News & Press Releases 142

Appendix 152

Methodology 152

Coverage 152

Secondary Research 152

Primary Research 152

Expert Panel Validation 152

Contact Us 152

Disclaimer 153

List of Tables

List of Tables

Number of Products under Development for Cancer Pain, H2 2016 13

Number of Products under Development for Cancer Pain – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Comparative Analysis by Unknown Stage Development, H2 2016 21

Products under Development by Companies, H2 2016 22

Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H2 2016 25

Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc, H2 2016 26

Cancer Pain – Pipeline by AngioChem Inc, H2 2016 27

Cancer Pain – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 28

Cancer Pain – Pipeline by Aphios Corp, H2 2016 29

Cancer Pain – Pipeline by AstraZeneca Plc, H2 2016 30

Cancer Pain – Pipeline by Benitec Biopharma Ltd, H2 2016 31

Cancer Pain – Pipeline by BioDelivery Sciences International Inc, H2 2016 32

Cancer Pain – Pipeline by ChironWells GmbH, H2 2016 33

Cancer Pain – Pipeline by Colby Pharmaceutical Company, H2 2016 34

Cancer Pain – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 35

Cancer Pain – Pipeline by Dompe Farmaceutici SpA, H2 2016 36

Cancer Pain – Pipeline by Fujimoto Pharmaceutical Corp, H2 2016 37

Cancer Pain – Pipeline by Grunenthal GmbH, H2 2016 38

Cancer Pain – Pipeline by GW Pharmaceuticals Plc, H2 2016 39

Cancer Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 40

Cancer Pain – Pipeline by Immupharma Plc, H2 2016 41

Cancer Pain – Pipeline by IntelGenx Corp, H2 2016 42

Cancer Pain – Pipeline by iX Biopharma Ltd, H2 2016 43

Cancer Pain – Pipeline by Kancera AB, H2 2016 44

Cancer Pain – Pipeline by Klaria Pharma Holding AB, H2 2016 45

Cancer Pain – Pipeline by Komipharm International Co Ltd, H2 2016 46

Cancer Pain – Pipeline by KPI Therapeutics Inc, H2 2016 47

Cancer Pain – Pipeline by Neurocentrx Pharma Ltd, H2 2016 48

Cancer Pain – Pipeline by Nippon Kayaku Co Ltd, H2 2016 49

Cancer Pain – Pipeline by Orion Oyj, H2 2016 50

Cancer Pain – Pipeline by Pain Therapeutics Inc, H2 2016 51

Cancer Pain – Pipeline by Pfizer Inc, H2 2016 52

Cancer Pain – Pipeline by Pharmaleads SA, H2 2016 53

Cancer Pain – Pipeline by Recordati SpA, H2 2016 54

Cancer Pain – Pipeline by Ribomic Inc., H2 2016 55

Cancer Pain – Pipeline by Trillium Therapeutics Inc, H2 2016 56

Cancer Pain – Pipeline by Virobay Inc, H2 2016 57

Cancer Pain – Pipeline by WEX Pharmaceuticals Inc, H2 2016 58

Cancer Pain – Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 59

Assessment by Monotherapy Products, H2 2016 60

Number of Products by Stage and Target, H2 2016 62

Number of Products by Stage and Mechanism of Action, H2 2016 65

Number of Products by Stage and Route of Administration, H2 2016 68

Number of Products by Stage and Molecule Type, H2 2016 70

Cancer Pain – Dormant Projects, H2 2016 141

Cancer Pain – Dormant Projects (Contd..1), H2 2016 142

Cancer Pain – Dormant Projects (Contd..2), H2 2016 143

Cancer Pain – Dormant Projects (Contd..3), H2 2016 144

Cancer Pain – Discontinued Products, H2 2016 145

List of Figures

List of Figures

Number of Products under Development for Cancer Pain, H2 2016 13

Number of Products under Development for Cancer Pain – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 60

Number of Products by Top 10 Targets, H2 2016 61

Number of Products by Stage and Top 10 Targets, H2 2016 61

Number of Products by Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Top 10 Routes of Administration, H2 2016 67

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 67

Number of Products by Top 10 Molecule Types, H2 2016 69

Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports